The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...

Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's ...

Osaka: Takeda has received approval from the European Commission (EC) for ADCETRIS (brentuximab vedotin) in combination with ...

Toriyama humbled his editor one day when Takeda visited his new house and noticed something absolutely unbelievable that he ...

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...

The drug has been approved in combination with the chemotherapy regimen etoposide, cyclophosphamide, doxorubicin, dacarbazine ...

"I am extremely proud that Takeda has been recognized as one of the top ten employers in the world for 2024. This confirms ...

This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

US drugmaker Protagonist Therapeutics (Nasdaq: PTGX) and Japan’s Takeda Pharma (TYO:4502) announced detailed results from the ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502 ...

Defending champion Yuka Saso's bid for a third U.S. Open title in five seasons got off to a rocky start with a 2-over-par 74.

Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's antibody-drug conjugate, Adcetrix, in combination with a chemotherapy regimen in ...